The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors

The NETest is a blood biomarker test for diagnosis and management of gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasia.
The test measures 51 individual circulating genes in 1 mL of blood and algorithmic analysis provides a numeric score of disease status.
The sensitivity and specificity of the test are respectively >95% and >90%. In head-to-head comparisons, the test is w4-fold more precise than CgA and for monitoring disease progress, it is w10-fold more accurate.
Clinically, the test can define the completeness of surgical resection, identify residual disease, monitor disease progression and determine efficacy of treatment. PRRT efficacy can be accurately (w95%) predicted using a Predictor Quotient gene set and Ki67 (PPQ).
Neuroendocrine disease status (stable/progressive) can be assessed by regular monitoring of blood NETest levels.